Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice

Endocrinology

Volumn 150, Issue 9, 2009, Pages 4033-4043

  Iakoubov, Roman ^a   Lauffer, Lina M ^a   Trivedi, Shivangi ^a   Kim, Young In J ^a,b,c   Brubaker, Patricia L ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; GLUCAGON LIKE PEPTIDE 2; MUCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DYSPLASIA; MOUSE; NONHUMAN; NUTRIENT; PRIORITY JOURNAL;

ANIMALS; AZOXYMETHANE; CELL PROLIFERATION; COLONIC NEOPLASMS; GLUCAGON-LIKE PEPTIDE 2; HUMANS; INTESTINES; MICE; MICE, INBRED C57BL;

EID: 69249150959     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-0295     Document Type: Article

References (51)

1. Drucker DJ 2005 Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab 1:22-31
2. Baggio LL, Huang Q, Brown TJ, Drucker DJ 2004 Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127:546-558
3. Hirotani Y, Yamamoto K, Yanaihara C, Balaspiri L, Yanaihara N, Kurokawa K 2000 Distinctive effects of glicentin, GLP-1 and GLP-2 on adaptive response to massive distal small intestine resection in rats. Ann NY Acad Sci 921:460-463
4. Brubaker PL, Izzo A, Hill M, Drucker DJ 1997 Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol 272:E1050-E1058
5. Guan X, Stoll B, Lu X, Tappenden KA, Holst JJ, Hartmann B, Burrin DG 2003 GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1. Gastroenterology 125:136-147
6. Bremholm L, Hornum M, Henriksen BM, Larsen S, Holst JJ 2009 Glucagon-like peptide-2 increases mesenteric blood flow in humans. Scand J Gastroenterol 44:314-319
7. Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH 2000 Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 47:112-119
8. Drucker DJ, Erlich P, Asa SL, Brubaker PL 1996 Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 93:7911-7916
9. Dubé PE, Brubaker PL 2007 Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 293:E460-E465
10. Shin ED, Estall JL, Izzo A, Drucker DJ, Brubaker PL 2005 Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice. Gastroenterology 128:1340-1353
11. Brubaker PL, Crivici A, Izzo A, Ehrlich P, Tsai CH, Drucker DJ 1997 Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2. Endocrinology 138:4837-4843
12. Thulesen J, Knudsen LB, Hartmann B, Hastrup S, Kissow H, Jeppesen PB, Ørskov C, Holst JJ, Poulsen SS 2002 The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist. Regul Pept 103:9-15
13. Tavares W, Drucker DJ, Brubaker PL 2000 Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. Am J Physiol Endocrinol Metab 278:E134-E139
14. Hartmann B, Harr MB, Jeppesen PB, Wojdemann M, Deacon CF, Mortensen PB, Holst JJ 2000 In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 85:2884-2888
15. Marier JF, Beliveau M, Mouksassi MS, Shaw P, Cyran J, Kesavan J, Wallens J, Zahir H, Wells D, Caminis J 2008 Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J Clin Pharmacol 48:1289-1299
16. Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, DeForest L, Cooper S, Brubaker PL 1997 Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol 15:673-677
17. Jeppesen PB, Sanguinetti EL, Buchman A, Howard L, Scolapio JS, Ziegler TR, Gregory J, Tappenden KA, Holst J, Mortensen PB 2005 Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 54:1224-1231
18. Dubé PE, Rowland KJ, Brubaker PL 2008 Glucagon-like peptide-2 activates β-catenin signaling in the mouse intestinal crypt: role of insulin-like growth factor-I. Endocrinology 149:291-301
19. Canavan C, Abrams KR, Mayberry J 2006 Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 23:1097-1104
20. Zisman TL, Rubin DT 2008 Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol 14:2662-2669
21. Thulesen J, Hartmann B, Hare KJ, Kissow H, Ørskov C, Holst JJ, Poulsen SS 2004 Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 53:1145-1150
22. Koehler JA, Harper W, Barnard M, Yusta B, Drucker DJ 2008 Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells. Cancer Res 68:7897-7904
23. Thurnherr N, Deschner EE, Stonehill EH, Lipkin M 1973 Induction of adenocarcinomas of the colon in mice by weekly injections of 1,2-dimethylhydrazine. Cancer Res 33:940-945
24. Shoemaker AR, Moser AR, Dove WF 1995 N-ethyl- N-nitrosourea treatment of multiple intestinal neoplasia (Min) mice: age-related effects on the formation of intestinal adenomas, cystic crypts, and epidermoid cysts. Cancer Res 55:4479-4485
25. Reitmair AH, Cai JC, Bjerknes M, Redston M, Cheng H, Pind MT, Hay K, Mitri A, Bapat BV, Mak TW, Gallinger S 1996 MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis. Cancer Res 56:2922-2926
26. Nambiar PR, Girnun G, Lillo NA, Guda K, Whiteley HE, Rosenberg DW 2003 Preliminary analysis of azoxymethane induced colon tumors in inbred mice commonly used as transgenic/knockout progenitors. Int J Oncol 22:145-150
27. Rosenberg DW, Giardina C, Tanaka T 2009 Mouse models for the study of colon carcinogenesis. Carcinogenesis 30:183-196
28. Dubé PE, Forse CL, Bahrami J, Brubaker PL 2006 The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology 131:589-605
29. Tsai CH, Hill M, Asa SL, Brubaker PL, Drucker DJ 1997 Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol 273:E77-E84
30. Bissahoyo A, Pearsall RS, Hanlon K, Amann V, Hicks D, Godfrey VL, Threadgill DW 2005 Azoxymethane is a genetic background-dependent colorectal tumor initiator and promoter in mice: effects of dose, route, and diet. Toxicol Sci 88:340-345
31. Ealey KN, Archer MC 2009 Elevated circulating adiponectin and elevated insulin sensitivity in adiponectin transgenic mice are not associated with reduced susceptibility to colon carcinogenesis. Int J Cancer 124:2226-2230
32. Bird RP 1987 Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 37:147-151
33. Caderni G, Femia AP, Giannini A, Favuzza A, Luceri C, Salvadori M, Dolara P 2003 Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: correlation with carcinogenesis. Cancer Res 63:2388-2392
34. Corpet DE, Taché S 2002 Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 43:1-21
35. Femia AP, Dolara P, Caderni G 2004 Mucin-depleted foci (MDF) in the colon of rats treated with azoxymethane (AOM) are useful biomarkers for colon carcinogenesis. Carcinogenesis 25:277-281
36. Femia AP, Bendinelli B, Giannini A, Salvadori M, Pinzani P, Dolara P, Caderni G 2005 Mucin-depleted foci have β-catenin gene mutations, altered expression of its protein, and are dose- and time-dependent in the colon of 1,2-dimethylhydrazine-treated rats. Int J Cancer 116:9-15
37. Garrison AP, Dekaney CM, von Allmen DC, Lund PK, Henning SJ, Helmrath MA 2009 Early but not late administration of glucagon-like peptide-2 following ileo-cecal resection augments putative intestinal stem cell expansion. Am J Physiol Gastrointest Liver Physiol 296:G643-G650
38. Kaji T, Tanaka H, Redstone H, Wallace LE, Holst JJ, Sigalet DL 2008 Temporal changes in the intestinal growth promoting effects of glucagon-like peptide 2 following intestinal resection. J Surg Res 152:271-280
39. Nelson DW, Sharp JW, Brownfield MS, Raybould HE, Ney DM 2007 Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat. Endocrinology 148:1954-1962
40. Yusta B, Huang L, Munroe D, Wolff G, Fantaske R, Sharma S, Demchyshyn L, Asa SL, Drucker DJ 2000 Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 119:744-755
41. Ørskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ 2005 GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept 124:105-112
42. Bjerknes M, Cheng H 2001 Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci USA 98:12497-12502
43. Guan X, Karpen HE, Stephens J, Bukowski JT, Niu S, Zhang G, Stoll B, Finegold MJ, Holst JJ, Hadsell D, Nichols BL, Burrin DG 2006 GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 130:150-164
44. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ 1999 Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91:620-625
45. Weber MM, Fottner C, Liu SB, Jung MC, Engelhardt D, Baretton GB 2002 Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 95:2086-2095
46. Sachdev D, Yee D 2007 Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6:1-12
47. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D 1999 Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 96:7324-7329
48. Diehl D, Oesterle D, Elmlinger MW, Hoeflich A, Wolf E, Lahm H 2006 IGF-II transgenic mice display increased aberrant colon crypt multiplicity and tumor volume after 1,2-dimethylhydrazine treatment. J Carcinog 5:24
49. Lovshin J, Yusta B, Iliopoulos I, Migirdicyan A, Dableh L, Brubaker PL, Drucker DJ 2000 Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine. Endocrinology 141:4194-4201
50. Kongkanuntn R, Bubb VJ, Sansom OJ, Wyllie AH, Harrison DJ, Clarke AR 1999 Dysregulated expression of β-catenin marks early neoplastic change in Apc mutant mice, but not all lesions arising in Msh2 deficient mice. Oncogene 18:7219-7225
51. Hata K, Tanaka T, Kohno H, Suzuki R, Qiang SH, Yamada Y, Oyama T, Kuno T, Hirose Y, Hara A, Mori H 2006 β-Catenin-accumulated crypts in the colonic mucosa of juvenile ApcMin/+ mice. Cancer Lett 239:123-128